Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
BeOne Medicines AG (6160.HK)
HKD185.80
-0.30 (-0.16%)
CH HKSE Healthcare Biotechnology
Address
Aeschengraben 27 4051
Basel, MA, CH
Basel, MA, CH
CEO
John V. Oyler
Website
beonemedicines.com
IPO
2018-08-08
ISIN CH1391448177
Description
BeiGene Ltd. is a global biotechnology enterprise, grounded in scientific research, committed to developing groundbreaking and economical pharmaceutical products. Its core mission is to enhance therapeutic outcomes and broaden patient access to critical medicines across the world. The company was co-founded by Xiao Dong Wang and John V. Oyler on October 28, 2010, and its corporate headquarters are situated in George Town, KY.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
HKD185.80
-0.30 (-0.16%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
5M
Beta
0.49
Float Shares
1.01B
Free Float %
75.2%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.95% | -0.95% | +0.53% | -9.83% | -17.86% | +4.91% | +40.90% | +30.08% | +0.80% | +75.79% | +75.79% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (13 ratings, all time)
Buy
Price Targets & DCF
Current price
185.80
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 3 | 0 |
| Buy | 14 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
5.51
Safe zone
Piotroski F-Score
7 / 9
Strong
MOAT Score
2 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
4 / 5
High
ROA Score
4 / 5
High
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+40.4% ★ Q1'26: +35.1% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+142.6% ★ Q1'26: +16,566.7% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+8.4% Q1'26: +10.6% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+8.4% ★ Q1'26: +16.5% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+35.6% ★ Q1'26: +44.1% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+7.8% Q1'26: +4.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×1.85× ★ Q1'26: 1.77× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 32 Rev. Ana. 8 EPS Ana. |
Dec 2027 34 Rev. Ana. 12 EPS Ana. |
Dec 2028 26 Rev. Ana. 7 EPS Ana. |
Dec 2029 31 Rev. Ana. 10 EPS Ana. |
Dec 2030 17 Rev. Ana. 5 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
8.82M
est: 7.62M (+15.7%)
|
1.07M
est: 4.55M (-76.5%)
|
238.39M
est: 246.55M (-3.3%)
|
198.22M
est: 189.50M (+4.6%)
|
428.21M
est: 432.20M (-0.9%)
|
308.87M
est: 332.42M (-7.1%)
|
1.18B
est: 1.20B (-2.0%)
|
1.42B
est: 1.42B (-0.1%)
|
2.46B
est: 2.42B (+1.5%)
|
3.81B
est: 3.72B (+2.4%)
|
5.35B
est: 5.31B (+0.8%)
|
6.45B
6.20B – 6.84B
+21.5% YoY
|
7.45B
6.89B – 8.11B
+15.5% YoY
|
8.40B
7.90B – 9.03B
+12.7% YoY
|
9.33B
8.78B – 10.03B
+11.1% YoY
|
10.43B
9.82B – 11.21B
+11.8% YoY
|
| EBITDA |
-55.20M
est: -5.43M (-917.4%)
|
-115.15M
est: -3.24M (-3,454.1%)
|
-93.70M
est: -175.52M (+46.6%)
|
-695.38M
est: -134.91M (-415.4%)
|
-941.27M
est: -1.74B (+45.8%)
|
-1.63B
est: -740.85M (-119.5%)
|
-1.39B
est: -1.53B (+9.1%)
|
-1.72B
est: -2.81B (+38.7%)
|
-1.12B
est: -5.29B (+78.8%)
|
-396.44M
est: -11.78B (+96.6%)
|
589.69M
est: -2.60B (+122.7%)
|
-3.16B
-3.35B – -3.03B
-21.5% YoY
|
-3.65B
-3.97B – -3.37B
-15.5% YoY
|
-4.11B
-4.42B – -3.87B
-12.7% YoY
|
-4.57B
-4.91B – -4.30B
-11.1% YoY
|
-5.11B
-5.49B – -4.81B
-11.8% YoY
|
| EBIT |
-56.75M
est: -5.55M (-922.7%)
|
-117.06M
est: -3.31M (-3,432.9%)
|
-98.46M
est: -179.50M (+45.1%)
|
-705.77M
est: -137.97M (-411.5%)
|
-959.89M
est: -1.84B (+47.8%)
|
-1.66B
est: -836.14M (-98.3%)
|
-1.44B
est: -1.73B (+16.7%)
|
-1.79B
est: -3.17B (+43.6%)
|
-1.21B
est: -5.97B (+79.8%)
|
-568.20M
est: -13.30B (+95.7%)
|
447.80M
est: -2.71B (+116.5%)
|
-3.30B
-3.50B – -3.17B
-21.5% YoY
|
-3.81B
-4.15B – -3.52B
-15.5% YoY
|
-4.29B
-4.62B – -4.04B
-12.7% YoY
|
-4.77B
-5.13B – -4.49B
-11.1% YoY
|
-5.33B
-5.73B – -5.02B
-11.8% YoY
|
| Net Income |
-57.10M
est: -247.32M (+76.9%)
|
-119.22M
est: -386.47M (+69.2%)
|
-93.11M
est: -149.12M (+37.6%)
|
-673.77M
est: -1.03B (+34.5%)
|
-950.58M
est: -1.76B (+45.9%)
|
-1.62B
est: -826.33M (-96.6%)
|
-1.46B
est: -1.71B (+14.6%)
|
-2.00B
est: -3.14B (+36.1%)
|
-881.71M
est: -5.90B (+85.1%)
|
-644.79M
est: -13.14B (+95.1%)
|
287.36M
est: 349.79M (-17.8%)
|
727.61M
606.24M – 979.11M
+108.0% YoY
|
1.08B
547.18M – 1.45B
+48.8% YoY
|
1.49B
1.38B – 1.64B
+38.0% YoY
|
1.69B
1.56B – 1.86B
+13.2% YoY
|
2.12B
1.96B – 2.33B
+25.4% YoY
|
| SGA |
7.31M
est: 7.29M (+0.4%)
|
20.10M
est: 4.35M (+361.9%)
|
62.60M
est: 235.69M (-73.4%)
|
195.39M
est: 181.16M (+7.9%)
|
388.25M
est: 413.17M (-6.0%)
|
600.18M
est: 317.78M (+88.9%)
|
990.12M
est: 698.99M (+41.7%)
|
1.28B
est: 1.28B (-0.5%)
|
1.50B
est: 2.42B (-37.7%)
|
1.83B
est: 2.39B (-23.5%)
|
2.04B
est: 3.42B (-40.3%)
|
4.15B
3.99B – 4.40B
+21.5% YoY
|
4.80B
4.43B – 5.22B
+15.5% YoY
|
5.40B
5.09B – 5.81B
+12.7% YoY
|
6.00B
5.65B – 6.46B
+11.1% YoY
|
6.71B
6.32B – 7.22B
+11.8% YoY
|
| EPS |
-0.14
est: -0.18 (+22.5%)
|
-0.30
est: -0.28 (-6.3%)
|
-0.17
est: -0.11 (-56.0%)
|
-0.93
est: -0.75 (-23.8%)
|
-1.22
est: -0.96 (-27.3%)
|
-1.39
est: -1.33 (-4.6%)
|
-1.17
est: -0.93 (-25.4%)
|
-1.49
est: -1.40 (-6.4%)
|
-0.65
est: -0.63 (-3.7%)
|
-0.47
est: -0.42 (-13.0%)
|
0.20
est: 0.24 (-15.7%)
|
0.49
0.41 – 0.66
+108.0% YoY
|
0.73
0.37 – 0.98
+48.8% YoY
|
1.01
0.94 – 1.11
+38.0% YoY
|
1.15
1.06 – 1.26
+13.2% YoY
|
1.44
1.33 – 1.58
+25.4% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | C+ | 2/5 | 1/5 | 4/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-06 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-05 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-04 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-30 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-29 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-28 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-27 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-24 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-23 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-15 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
1.84B
OE per share TTM
1.24
Owner's Yield
0.68%
Maintenance CapEx ratio
64.81%
Maint CapEx / Avg PPE
47.9%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | OLD MISSION CAPITAL LLC | — -87.9K (-100.0%) | — -21.3M (-100.0%) | 0.00% -0.006 pp | 0.00% -0.355 pp | HKD— | 2 qtrs SOLD |
Ownership breakdown by holder
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
40.7K
Shares Outstanding
1.35B
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Xiaodong Wang | Co-Chairman of Scientific Advisory Board, Non-Executive Director & Co-Founder | 33M | — |
| John V. Oyler | Co-Founder, Executive Chairman & Chief Executive Officer | 23M | male |
| Wang Lai | President and Global Head of Research & Development | 10M | male |
| Aaron Rosenberg | Chief Financial Officer | 10M | male |
| Chan Lee | General Counsel, Senior VP & Corporate Secretary | 10M | male |
| Liza Heapes | Head of Investor Relations | — | female |
| Marcello Damiani | Chief Technology Officer | — | male |
| Graham Hardiman | Global Head of Human Resources | — | male |
| Titus Ball | Vice President & Chief Accounting Officer | — | male |
| Eleanor Duff | Senior Vice President & Head of Corporate Communications | — | female |
| Mark Lanasa | Senior Vice President & Chief Medical Officer for Solid Tumors | — | — |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 6160.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
